Explore the key elements of a diversity action plan for research, as explained in recommendations from the U.S. Food and Drug Administration (FDA).
Since December 2022, diversity action plans are required for Phase III clinical trials, and these should include considerations of race, ethnicity, age, sex, gender, geographic location, and socioeconomic status. Participants in this webinar will learn how to craft successful clinical trial diversity action plans aimed at delivering meaningful data on drug safety and efficacy from their study site to sponsors.
Upon completion of this continuing education program, participants should be able to:
Use health disparities knowledge and data to demonstrate validity of clinical trial recruitment methods and goals.
Construct operational measures to inform the diversity trial plan.
Gelise Thomas, Assistant Director, Strategic DEI & Health Disparities, Case Western Reserve University